Ixekizumab for the treatment of erythrodermic psoriasis triggered by durvalumab-tremelimumab in a cancer patient
Eur J Dermatol
.
2021 Aug 26;31(4):564-565.
doi: 10.1684/ejd.2021.4087.
Online ahead of print.
Authors
Arrieta Vinaixa Aranzazu
1
,
Víctor Morillas-Lahuerta
1
,
María Blanco De Tord
1
,
José-Manuel Carrascosa Carrillo
1
Affiliation
1
Dermatology department, Hospital Universitario Germans Trias i Pujol, Carretera de Canyet, s/n, 08916 Badalona, Spain.
PMID:
34463279
PMCID:
PMC8572685
DOI:
10.1684/ejd.2021.4087
No abstract available